Things You Should Know About Sustained-Delivery Anti-VEGF.

Szczegóły
Abstrakt

Tytuł:: Things You Should Know About Sustained-Delivery Anti-VEGF.
Autorzy:: Khanani, Arshad M.
Temat:: THERAPEUTIC use of monoclonal antibodies
RETINAL degeneration
NEOVASCULARIZATION inhibitors
CLINICAL trials
CONTINUING education units
PATHOLOGIC neovascularization
VASCULAR endothelial growth factors
Źródło:: Ophthalmology Times. Nov2021, Vol. 46 Issue 18, p39-41. 3p.
: Periodyk

Pełny tekst

The article discusses several things about sustained delivery of anti-vascular endothelial growth factor therapies. Topics covered include how clinical practice links treatment frequency with visual outcomes, how emerging neovascular age-related macular degeneration (nAMD) therapies take a variety of approaches and the availability of phase 3 results for emerging nAMD therapies.

Informacja